Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Precision Medicine
100%
Cancer Immunotherapy
100%
Immune Targets
100%
Neoantigen
100%
Cancer Patients
40%
Chimeric Antigen Receptor T Cells (CAR-T)
40%
T Cell Receptor
40%
CD19
40%
Solid Cancer
40%
Clinical Trials
20%
Target Antigen
20%
Immune System
20%
Cancer Types
20%
Cancer Therapy
20%
Signaling Molecules
20%
Malignant Cells
20%
NY-ESO-1
20%
Next-generation Sequencing
20%
Cancer Antigen
20%
Receptor-based
20%
T Cell Immunotherapy
20%
Sipuleucel-T
20%
FDA-approved Drugs
20%
Metastatic Cancer
20%
Blood Cancer
20%
Provenge
20%
NY-ESO-1-specific T Cells
20%
Inhibitory Signaling
20%
Co-inhibitory
20%
Anti-CTLA-4
20%
Ipilimumab
20%
Chimeric Antigen Receptor T-cell Therapy
20%
Keytruda
20%
Pembrolizumab
20%
Checkpoint Blockade Therapy
20%
Oncoimmunology
20%
Advanced Research
20%
Yervoy
20%
Anti-programmed death-1 Monoclonal Antibody
20%
Medicine and Dentistry
Malignant Neoplasm
100%
Cancer Immunotherapy
100%
Personalized Medicine
100%
Immunotherapy
60%
T Lymphocyte Receptor
40%
Sipuleucel T
40%
Ipilimumab
40%
Chimeric Antigen Receptor T-Cell Immunotherapy
40%
Pembrolizumab
40%
Clinical Trial
20%
Medicine
20%
Clinical Study
20%
Metastatic Carcinoma
20%
Immune System
20%
Chimeric Antigen Receptor
20%
Tumor Antigen
20%
Cancer Therapy
20%
Signaling Molecule
20%
CTLA-4
20%
CD19 Antigen
20%
Immunology
20%
Programmed Cell Death
20%
Next Generation Sequencing
20%
Hematological Cancer
20%
Immunology and Microbiology
Neoantigen
100%
Cancer Immunotherapy
100%
Immunotherapy
80%
T Cell Receptor
40%
Chimeric Antigen Receptor
40%
Sipuleucel-T
40%
Ipilimumab
40%
Pembrolizumab
40%
Next Generation Sequencing
20%
T Cell
20%
Tumor Antigen
20%
Immune System
20%
CTLA-4
20%
CD19 Antigen
20%
Immunology
20%
CD19
20%
Programmed Cell Death 1
20%
Chimeric Antigen Receptor T-Cell Therapy
20%